Protein Engineering

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the protein design and engineering market in the short to mid-term and long term.

Chapter 3 provides a general introduction to protein design and engineering, featuring information on various steps involved in the overall process. Further, it provides a detailed discussion on different methods of protein design and engineering. In addition, the chapter includes details related to the various applications and challenges associated with protein design and engineering. The chapter concludes with a discussion on the key growth drivers, as well as upcoming trends in this field.

Chapter 4 includes detailed assessment of the overall landscape of companies offering protein design and engineering services to various organizations, including pharma / biotech firms, CROs and research / academic institutes, along with information on their year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also provides details related to protein design and protein engineering service(s) offered (protein sequencing, protein library generation, protein screening, protein characterization, protein purification, de-novo protein synthesis and in-silico analysis), additional services offered (protein expression, drug discovery, protein-protein interaction analysis, protein identification, bio imaging of proteins, protein extraction and biological pathway identification), type of protein engineering approach used (directed evolution, rational designing and semi- rational designing), type of protein (antibodies, enzymes, peptides, vaccines and others), type of application (therapeutics and diagnostics) and type of protein expression (cell surface and cell free). 

Chapter 5 provides a competitiveness analysis of protein design and engineering service providers, segmented into three categories, namely small (1-50 employees), mid-sized (51-500 employees), and large companies (>500 employees). Within the peer group, companies were ranked based on various relevant parameters, such as supplier power (based on the experience) and their respective capabilities (number of protein design and engineering services offered, type of technique used, protein engineering approaches used, number of additional services offered, application areas and type of protein expression).

Chapter 6 includes detailed profiles of key players offering protein design and engineering services in North America. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on protein design and engineering services offered, recent developments and an informed future outlook.

Chapter 7 includes detailed profiles of key players offering protein design and engineering services in Europe. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on protein design and engineering services offered, recent developments and an informed future outlook.

Chapter 8 includes detailed profiles of key players offering protein design and engineering services in Asia Pacific. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on protein design and engineering services offered, recent developments and an informed future outlook.

Chapter 9 provides a detailed assessment of the current market landscape of protein design and engineering technology providers, featuring information on their year of establishment, company size (in terms of employee count) and location of headquarters. In addition, the chapter highlights an in-depth analysis of various protein design and engineering technologies based on type of protein design and protein engineering service(s) supported (protein sequencing, protein library generation, protein screening, protein characterization, de novo protein synthesis and in-silico analysis), additional services supported (drug discovery, protein-protein interaction analysis and protein expression), type of protein engineering approach used (rational designing, directed evolution and semi-rational designing), type of proteins (proteins / peptides, antibodies, enzymes, cytokines and viruses) and type of application (therapeutics and diagnostics).

Chapter 10 presents an insightful 2×2 representation of the competitiveness analysis of various protein design and engineering technologies segregated into two peer groups based on the company size of their respective technology provider, namely small (1-50 employees) and mid-sized companies (51-500 employees). Within the peer group, technologies were ranked based on various relevant parameters, such as supplier power (based on the experience / expertise of the technology provider) and key technology specifications (number of protein design and protein engineering services supported, number of additional services supported, type of proteins and type of application).

Chapter 11 includes detailed profiles of key players offering protein design and engineering technologies. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), information on protein design and engineering technologies offered, recent developments and an informed future outlook.

Chapter 12 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, during the period 2017-2021 . Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership (R&D agreements, technology licensing agreements, product development and commercialization agreements, research agreements, service alliances, product development agreements, acquisitions / mergers, technology / software development agreements and other related agreements), and regional distribution of the collaborations.

Chapter 13 present an in-depth analysis of over 90 protein / peptide based therapy developers that are likely to partner with protein design and engineering services and technology providers, based on several relevant parameters, such as developer strength (on the basis of company size and its experience), pipeline strength and maturity (on the basis of number of drugs in pipeline and their stage of development) and therapeutic area.

Chapter 14 provides an in-depth over 550 patents filed / granted related to protein design and engineering, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, publication year, regional applicability, CPC symbols, emerging focus areas, type of applicant, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.

Chapter 15 provides a detailed analysis of completed, ongoing and planned clinical studies of various protein / peptide based therapies on relevant parameters, such as trial registration year, trial recruitment status, phase of development, target patient segment, type of sponsor, most active players (in terms of number of registered trials conducted) and key geographical regions.

Chapter 16 presents case study presenting the key characteristics of novel peptide therapeutics, along with information on their applications and advantages, as well as key challenges associated with their development process.

Chapter 17 presents an insightful market forecast analysis, highlighting the future potential of protein design and engineering services market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented across important market segments, namely [A] type of protein engineering approach used (rational designing, directed evolution and semi - rational designing), [B] type of protein (antibodies, peptides, enzymes, vaccines and others), [C] type of application (therapeutics and diagnostics), [D] type of end user (pharma / biotech firms, CROs and research / academic institutes) and [E] key geographies (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). 

Chapter 18 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 19 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Roman Badik (Chief Executive Officer, Enantis), Haibin Chen (Vice President, Enzymaster) and Naveen Kulkarni (Chief Executive Officer, Quantumzyme).

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 21 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Protein Design and Engineering
3.3. Protein Design and Engineering Process
3.3.1. Protein Sequencing
3.3.2. Protein Library Generation
3.3.3. Protein Screening
3.3.4. Protein Expression
3.3.5. Protein Characterization
3.3.6. Protein Quantification
3.3.7. Protein Purification
3.3.8. In-Silico Analysis

3.4. Methods Used for Protein Design and Engineering
3.4.1 Rational Method
3.4.2 Irrational Method / Directed Evolution Method
3.4.3. De-Novo Protein Design Method
3.4.4. Semi-Rational Method / Combinatorial Method

3.5. Applications of Protein Design and Engineering in Pharmaceutical Industry
3.5.1. Disease Diagnosis
3.5.2. Drug Discovery
3.5.3. Development of Protein based Therapeutics
3.5.4. Enzyme Engineering
3.5.5. Antibody Engineering
3.5.6. Virus Engineering

3.6. Challenges Associated with Protein Design and Engineering
3.7. Concluding Remarks

4. MARKET LANDSCAPE: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS
4.1. Chapter Overview
4.2. Protein Design and Engineering Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Protein Design and Engineering Service(s) Offered
4.2.5. Analysis by Additional Services Offered
4.2.6. Analysis by Type of Protein Engineering Approach Used
4.2.7. Analysis by Type of Protein
4.2.8. Analysis by Type of Application
4.2.9. Analysis by Type of Protein Expression

5. PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Protein Design and Engineering Services: Company Competitiveness Analysis
5.4.1. Company Competitiveness Analysis: Small Service Providers
5.4.2. Company Competitiveness Analysis: Mid-Sized Service Providers
5.4.3. Company Competitiveness Analysis: Large Service Providers

6. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. ATUM
6.2.1. Company Overview
6.2.2. Protein Design and Engineering Service Offerings
6.2.3. Protein Design and Engineering Technologies
6.2.4. Recent Developments and Future Outlook

6.3. Creative BioMart
6.3.1. Company Overview
6.3.2. Protein Design and Engineering Service Offerings
6.3.3. Recent Developments and Future Outlook

6.4. Creative Biostructure
6.4.1. Company Overview
6.4.2. Protein Design and Engineering Service Offerings
6.4.3. Recent Developments and Future Outlook

6.5. Creative Enzymes
6.5.1. Company Overview
6.5.2. Protein Design and Engineering Service Offerings
6.5.3. Recent Developments and Future Outlook

7. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS IN EUROPE
7.1. Chapter Overview
7.1. Absolute Antibody
7.1.1. Company Overview
7.1.2. Protein Design and Engineering Service Offerings
7.1.3. Recent Developments and Future Outlook

7.2. EUCODIS Bioscience
7.2.1. Company Overview
7.2.2. Protein Design and Engineering Service Offerings
7.2.3. Protein Design and Engineering Technologies
7.2.4. Recent Developments and Future Outlook

7.3. Fusion Antibodies
7.3.1. Company Overview
7.3.2. Protein Design and Engineering Service Offerings
7.3.3. Protein Design and Engineering Technologies
7.3.4. Financial Information
7.3.5. Recent Developments and Future Outlook

7.4. Innovagen
7.4.1. Company Overview
7.4.2. Protein Design and Engineering Service Offerings
7.4.3. Recent Developments and Future Outlook

7.5. ZYMVOL
7.5.1. Company Overview
7.5.2. Protein Design and Engineering Service Offerings
7.5.3. Protein Design and Engineering Technologies
7.5.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING SERVICE PROVIDERS IN ASIA PACIFIC
8.1. Chapter Overview
8.2. Averring Biotech
8.2.1. Company Overview
8.2.2. Protein Design and Engineering Service Offerings
8.2.3. Recent Developments and Future Outlook

8.3. EnzymeWorks
8.3.1. Company Overview
8.3.2. Protein Design and Engineering Service Offerings
8.3.3. Recent Developments and Future Outlook

8.4. GeNext Genomics
8.4.1. Company Overview
8.4.2. Protein Design and Engineering Service Offerings
8.4.3. Recent Developments and Future Outlook

8.5. Quantumzyme
8.5.1. Company Overview
8.5.2. Protein Design and Engineering Service Offerings
8.5.3. Protein Design and Engineering Technologies
8.5.4. Recent Developments and Future Outlook

9. MARKET LANDSCAPE: PROTEIN DESIGN AND ENGINEERING TECHNOLOGY PROVIDERS
9.1. Chapter Overview
9.2. Protein Design and Engineering Technology Providers: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Analysis by Protein Design and Engineering Service(s) Supported
9.2.5. Analysis by Additional Services Supported
9.2.6. Analysis by Type of Protein Engineering Approach Used
9.2.7. Analysis by Type of Protein
9.2.8. Analysis by Type of Application

10. PROTEIN DESIGN AND ENGINEERING TECHNOLOGIES: COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Protein Design and Engineering Technologies: Competitiveness Analysis
10.4.1. Technology Competitiveness Analysis: Small Technology Providers
10.4.2. Technology Competitiveness Analysis: Mid-sized Technology Providers

11. COMPANY PROFILES: PROTEIN DESIGN AND ENGINEERING TECHNOLOGY PROVIDERS
11.1. Chapter Overview
11.2. Arzeda
11.2.1. Company Overview
11.2.2. Protein Design and Engineering Technologies
11.2.3. Recent Developments and Future Outlook

11.3. Cyrus Biotechnology
11.3.1. Company Overview
11.3.2. Protein Design and Engineering Technologies
11.3.3. Recent Developments and Future Outlook

11.4. Enzymaster
11.4.1. Company Overview
11.4.2. Protein Design and Engineering Technologies
11.4.3. Recent Developments and Future Outlook

11.5. Innovative Targeting Solutions
11.5.1. Company Overview
11.5.2. Protein Design and Engineering Technologies
11.5.3. Recent Developments and Future Outlook

11.6. Proteus
11.6.1. Company Overview
11.6.2. Protein Design and Engineering Technologies
11.6.3. Recent Developments and Future Outlook

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Protein Design and Engineering Market: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Focus Area
12.3.5. Most Active Players: Analysis by Number of Partnerships
12.3.6. Geographical Analysis
12.3.6.1. Region-wise Distribution
12.3.6.2. Country-wise Distribution

13. LIKELY PARTNERS ANALYSIS
13.1. Chapter Overview
13.2. Scoring Criteria and Key Assumptions
13.3. Scope and Methodology
13.4. Potential Strategic Partners
13.4.1. Potential Strategic Partners in North America
13.4.1.1. Most Likely Partners in North America
13.4.1.2. Likely Partners in North America
13.4.1.3. Less Likely Partners in North America

13.4.2. Potential Strategic Partners in Europe
13.4.2.1. Most Likely Partners in Europe
13.4.2.2. Likely Partners in Europe
13.4.2.3. Less Likely Partners in Europe

13.4.3. Potential Strategic Partners in Asia Pacific
13.4.3.1. Most Likely Partners in Asia Pacific
13.4.3.2. Likely Partners in Asia Pacific
13.4.3.3. Less Likely Partners in Asia Pacific

14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Protein Design and Engineering Market: Patent Analysis
14.3.1. Analysis by Application Year
14.3.2. Analysis by Publication Year
14.3.3. Analysis by Geography
14.3.4. Analysis by CPC Symbols
14.3.5. Emerging Focus Areas
14.3.6. Analysis by Type of Organization
14.3.7. Leading Players: Analysis by Number of Patents

14.4. Protein Design and Engineering Market: Patent Benchmarking Analysis
14.4.1. Analysis by Patent Characteristics

14.5. Protein Design and Engineering Market: Patent Valuation Analysis
14.6. Leading Patents by Number of Citations

15. CLINICAL TRIAL ANALYSIS
15.1. Chapter overview
15.2. Scope and Methodology
15.3. Protein / Peptide Therapeutics: Clinical Trial Analysis
15.3.1. Analysis by Trial Registration Year
15.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
15.3.3. Analysis by Trial Phase
15.3.4. Analysis by Recruitment Status
15.3.5. Analysis by Type of Sponsor / Collaborator
15.3.6. Analysis by Target Patient Segment
15.3.7. Leading Industry Players: Analysis by Number of Registered Trials
15.3.8. Leading Non-Industry Players: Analysis by Number of Registered Trials
15.3.9. Analysis of Clinical Trials by Geography
15.3.10. Analysis of Enrolled Patient Population by Geography

16. CASE STUDY: NOVEL PEPTIDE THERAPEUTICS
16.1. Chapter Overview
16.2. Overview of Novel Peptide Therapeutics
16.3. Advantages and Applications of Novel Peptide Therapeutics
16.4. Key Challenges Associated with Novel Peptide Therapeutics

17. MARKET FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Global Protein Design and Engineering Services Market, 2021-2035
17.4. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein Engineering Approach Used
17.5. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein
17.6. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Application
17.7. Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of End User
17.8. Protein Design and Engineering Services Market, 2021-2035: Distribution by Region
17.8.1. Protein Design and Engineering Services Market in North America, 2021-2035
17.8.2. Protein Design and Engineering Services Market in Europe, 2021-2035
17.8.3. Protein Design and Engineering Services Market in Asia Pacific, 2021-2035
17.8.4. Protein Design and Engineering Services Market in Latin America, 2021-2035
17.8.5. Protein Design and Engineering Services Market in MENA, 2021-2035
17.8.6. Protein Design and Engineering Services Market in Rest of the World, 2021-2035

18. CONCLUDING REMARKS

19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Enantis
19.2.1. Company Snapshot
19.2.2. Interview Transcript: Roman Badik, Chief Executive Officer

19.3. Enzymaster
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Haibin Chen, Vice President

19.4. Quantumzyme
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Naveen Kulkarni, Chief Executive Officer

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape of Protein Design and Engineering Service Providers
Figure 2.2 Executive Summary: Overall Market Landscape of Protein Design and Engineering Technology Providers
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Patent Analysis
Figure 2.5 Executive Summary: Clinical Trial Analysis
Figure 2.6 Executive Summary: Market Forecast
Figure 3.1 Protein Design and Engineering Process
Figure 3.2 Directed Evolution Process
Figure 3.3 Protein Design and Engineering Applications
Figure 4.1 Protein Design and Engineering Service Providers: Distribution by Year of Establishment
Figure 4.2 Protein Design and Engineering Service Providers: Distribution by Company Size
Figure 4.3 Protein Design and Engineering Service Providers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Protein Design and Engineering Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Protein Design and Engineering Service Providers: Distribution by Company Size and Location of Headquarters
Figure 4.6 Protein Design and Engineering Service Providers: Distribution by Type of Protein Design and Engineering Service(s) Offered
Figure 4.7 Protein Design and Engineering Service Providers: Distribution by Additional Services Offered
Figure 4.8 Protein Design and Engineering Service Providers: Distribution by Type of Protein Engineering Approach Used
Figure 4.9 Protein Design and Engineering Service Providers: Distribution by Type of Protein
Figure 4.10 Protein Design and Engineering Service Providers: Distribution by Type of Application
Figure 4.11 Protein Design and Engineering Service Providers: Distribution by Type of Protein Expression
Figure 5.1 Company Competitiveness Analysis: Dot-plot Analysis of Small Service Providers
Figure 5.2 Company Competitiveness Analysis: Small Service Providers
Figure 5.3 Company Competitiveness Analysis: Mid-Sized Service Providers
Figure 5.4 Company Competitiveness Analysis: Large Service Providers
Figure 7.1 Fusion Antibodies: Annual Revenues, 2016-2020 (EUR Million)
Figure 9.1 Protein Design and Engineering Technology Providers: Distribution by Year of Establishment
Figure 9.2 Protein Design and Engineering Technology Providers: Distribution by Company Size
Figure 9.3 Protein Design and Engineering Technology Providers: Distribution by Location of Headquarters (Region-wise)
Figure 9.4 Protein Design and Engineering Technology Providers: Distribution by Location of Headquarters (Country-wise)
Figure 9.5 Protein Design and Engineering Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 9.6 Protein Design and Engineering Technologies: Distribution by Type of Protein Design and Engineering Service(s) Supported
Figure 9.7 Protein Design and Engineering Technologies: Distribution by Additional Service(s) Supported
Figure 9.8 Protein Design and Engineering Technologies: Distribution by Type of Protein Engineering Approach Used
Figure 9.9 Protein Design and Engineering Technologies: Distribution by Type of Protein
Figure 9.10 Protein Design and Engineering Technologies: Distribution by Type of Application
Figure 10.1 Technology Competitiveness Analysis: Small Technology Providers
Figure 10.2 Technology Competitiveness Analysis: Mid-sized Technology Providers
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2021
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 12.5 Partnerships and Collaborations: Distribution by Number of Partnerships
Figure 12.6 Most Active Players: Distribution by Location of Headquarters (Region-wise)
Figure 12.7 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Figure 14.1 Patent Analysis: Distribution by Type of Patent
Figure 14.2 Patent Analysis: Distribution by Application Year
Figure 14.3 Patent Analysis: Cumulative Distribution by Publication Year
Figure 14.4 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 14.5 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 14.6 Patent Analysis: Distribution by CPC Symbols
Figure 14.7 Patent Analysis: Emerging Focus Areas
Figure 14.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Figure 14.9 Leading Industry Players: Distribution by Number of Patents
Figure 14.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 14.11 Leading Patent Assignees: Distribution by Number of Patents
Figure 14.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 14.13 Patent Analysis: Distribution of Patents by Age (2019-2021)
Figure 14.14 Protein Design and Engineering: Patent Valuation
Figure 15.1 Clinical Trial Analysis: Scope and Methodology
Figure 15.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2021
Figure 15.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2021
Figure 15.4 Clinical Trial Analysis: Distribution by Trial Phase and Number of Registered Trials
Figure 15.5 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Figure 15.6 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 15.7 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status, Pre-2010-2021
Figure 15.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 15.9 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 15.10 Leading Industry Players: Distribution by Number of Registered Trials
Figure 15.11 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 15.12 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 15.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 17.1 Global Protein Design and Engineering Services Market, 2021-2035 (USD Billion)
Figure 17.2 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein Engineering Approach Used (USD Billion)
Figure 17.3 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein (USD Billion)
Figure 17.4 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Application (USD Billion)
Figure 17.5 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of End User (USD Billion)
Figure 17.6 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Region (USD Billion)
Figure 17.7 Protein Design and Engineering Services Market in North America, 2021-2035 (USD Billion)
Figure 17.8 Protein Design and Engineering Services Market in Europe, 2021-2035 (USD Billion)
Figure 17.9 Protein Design and Engineering Services Market in Asia Pacific, 2021-2035 (USD Billion)
Figure 17.10 Protein Design and Engineering Services Market in Latin America, 2021-2035 (USD Billion)
Figure 17.11 Protein Design and Engineering Services Market in MENA, 2021-2035 (USD Billion)
Figure 17.12 Protein Design and Engineering Services Market in Rest of the World, 2021-2035 (USD Billion)
Figure 18.1 Concluding Remarks: Overall Market Landscape of Protein Design and Engineering Service Providers
Figure 18.2 Concluding Remarks: Overall Market Landscape of Protein Design and Engineering Technology Providers
Figure 18.3 Concluding Remarks: Partnerships and Collaborations
Figure 18.4 Concluding Remarks: Patent Analysis
Figure 18.5 Concluding Remarks: Clinical Trial Analysis
Figure 18.6 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 List of Protein Design and Engineering Service Providers
Table 4.2 Protein Design and Engineering Service Providers: Information on Type of Protein Design an Engineering Service(s) offered and Additional Service(s) offered
Table 4.3 Protein Design and Engineering Service Providers: Information on Type of Protein Engineering Approach Used, Type of Protein, Type of Application and Type of Protein Expression
Table 6.1 Leading Protein Design and Engineering Service Providers in North America
Table 6.2 ATUM: Company Snapshot
Table 6.3 ATUM: Protein Design and Engineering Service Offerings
Table 6.4 ATUM: Protein Design and Engineering Technologies
Table 6.5 ATUM: Recent Developments and Future Outlook
Table 6.6 Creative BioMart: Company Snapshot
Table 6.7 Creative BioMart: Protein Design and Engineering Service Offerings
Table 6.8 Creative Biostructure: Company Overview
Table 6.9 Creative Biostructure: Protein Design and Engineering Service Offerings
Table 6.10 Creative Enzyme: Company Snapshot
Table 6.11 Creative Enzyme: Protein Design and Engineering Service Offerings
Table 7.1 Leading Protein Design and Engineering Service Providers in Europe
Table 7.2 Absolute Antibody: Company Snapshot
Table 7.3 Absolute Antibody: Protein Design and Engineering Service Offerings
Table 7.5 EUCODIS Bioscience: Company Snapshot
Table 7.6 EUCODIS Bioscience: Protein Design and Engineering Service Offerings
Table 7.7 EUCODIS Bioscience: Protein Design and Engineering Technologies
Table 7.8 Fusion Antibodies: Company Snapshot
Table 7.9 Fusion Antibodies: Protein Design and Engineering Service Offerings
Table 7.10 Fusion Antibodies: Protein Design and Engineering Technologies
Table 7.11 Fusion Antibodies: Recent Developments and Future Outlook
Table 7.12 Innovagen: Company Snapshot
Table 7.13 Innovagen: Protein Design and Engineering Service Offerings
Table 7.14 ZYMVOL: Company Snapshot
Table 7.15 ZYMVOL: Protein Design and Engineering Service Offerings
Table 7.16 ZYMVOL: Protein Design and Engineering Technologies
Table 7.17 ZYMVOL: Recent Developments and Future Outlook
Table 8.1 Leading Protein Design and Engineering Service Providers in Asia Pacific
Table 8.2 Averin Biotech: Company Snapshot
Table 8.3 Averin Biotech: Protein Design and Engineering Service Offerings
Table 8.4 EnzymeWorks: Company Snapshot
Table 8.5 EnzymeWorks: Protein Design and Engineering Service Offerings
Table 8.6 EnzymeWorks: Recent Developments and Future Outlook
Table 8.7 GeNext Genomics: Company Snapshot
Table 8.8 GeNext Genomics: Protein Design and Engineering Service Offerings
Table 8.9 Quantumzyme: Company Snapshot
Table 8.10 Quantumzyme: Protein Design and Engineering Service Offerings
Table 8.11 Quantumzyme: Protein Design and Engineering Technologies
Table 8.12 Quantumzyme: Recent Developments and Future Outlook
Table 9.1 List of Protein Design and Engineering Technology Providers
Table 9.2 Protein Design and Engineering Technologies: Information on Type of Protein Design and Engineering Service(s) Supported and Additional Service(s) Supported
Table 9.3 Protein Design and Engineering Technologies: Information on Type of Protein Engineering Approach Used, Type of Protein, Type of Application and Type of Protein Expression
Table 11.1 Leading Protein Design and Engineering Technology Providers
Table 11.2 Arzeda: Company Snapshot
Table 11.3 Arzeda: Protein Design and Engineering Technologies
Table 11.4 Arzeda: Recent Developments and Future Outlook
Table 11.5 Cyrus Biotechnology: Company Snapshot
Table 11.6 Cyrus Biotechnology: Protein Design and Engineering Technologies
Table 11.7 Cyrus Biotechnology: Recent Developments and Future Outlook
Table 11.8 Enzymaster: Company Snapshot
Table 11.9 Enzymaster: Protein Design and Engineering Technologies
Table 11.10 Enzymaster: Recent Developments and Future Outlook
Table 11.11 Innovative Targeting Solutions: Company Snapshot
Table 11.12 Innovative Targeting Solutions: Protein Design and Engineering Technologies
Table 11.13 Innovative Targeting Solutions: Recent Developments and Future Outlook
Table 11.14 Proteus: Company Snapshot
Table 11.15 Proteus: Protein Design and Engineering Technologies
Table 11.16 Proteus: Recent Developments and Future Outlook
Table 12.1 Protein Design and Engineering Market: List of Partnerships and Collaborations, 2017-2021
Table 13.1 Most Likely Partners based in North America
Table 13.2 Likely Partners based in North America
Table 13.3 Less Likely Partners based in North America
Table 13.4 Most Likely Partners based in Europe
Table 13.5 Likely Partners based in Europe
Table 13.6 Less Likely Partners based in Europe
Table 13.7 Most Likely Partners based in Asia Pacific
Table 13.8 Likely Partners based in Asia Pacific
Table 13.9 Less Likely Partners based in Asia Pacific
Table 14.1 Patent Analysis: Prominent CPC Symbols
Table 14.2 Patent Analysis: Most Popular CPC Symbols
Table 14.3 Patent Analysis: List of Top CPC Symbols
Table 14.4 Patent Analysis: Summary of Benchmarking Analysis
Table 14.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 14.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 14.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 16.1 Novel Peptide Therapeutics: Development Pipeline
Table 19.1 Enantis: Company Snapshot
Table 19.2 Enzymaster: Company Snapshot
Table 19.3 Quantumzyme: Company Snapshot
Table 20.1 Protein Design and Engineering Service Providers: Distribution by Year of Establishment
Table 20.2 Protein Design and Engineering Service Providers: Distribution by Company Size
Table 20.3 Protein Design and Engineering Service Providers: Distribution by Location of Headquarters (Region-wise)
Table 20.4 Protein Design and Engineering Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 20.5 Protein Design and Engineering Service Providers: Distribution by Company Size and Location of Headquarters
Table 20.6 Protein Design and Engineering Service Providers: Distribution by Type of Protein Design and Engineering Service(s) Offered
Table 20.7 Protein Design and Engineering Service Providers: Distribution by Additional Services Offered
Table 20.8 Protein Design and Engineering Service Providers: Distribution by Type of Protein Engineering Approach Used
Table 20.9 Protein Design and Engineering Service Providers: Distribution by Type of Protein
Table 20.10 Protein Design and Engineering Service Providers: Distribution by Type of Application
Table 20.11 Protein Design and Engineering Service Providers: Distribution by Type of Protein Expression
Table 20.12 Fusion Antibodies: Annual Revenues, 2016-2020 (EUR Million)
Table 20.13 Protein Design and Engineering Technology Providers: Distribution by Company Size
Table 20.14 Protein Design and Engineering Technology Providers: Distribution by Location of Headquarters (Region-wise)
Table 20.15 Protein Design and Engineering Technology Providers: Distribution by Location of Headquarters (Country-wise)
Table 20.16 Protein Design and Engineering Technology Providers: Distribution by Company Size and Location of Headquarters
Table 20.17 Protein Design and Engineering Technologies: Distribution by Type of Protein Design and Engineering Service(s) Supported
Table 20.18 Protein Design and Engineering Technologies: Distribution by Additional Services Supported
Table 20.19 Protein Design and Engineering Technologies: Distribution by Type of Protein Engineering Approach Used
Table 20.20 Protein Design and Engineering Technologies: Distribution by Type of Protein
Table 20.21 Protein Design and Engineering Technologies: Distribution by Type of Application
Table 20.22 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2021
Table 20.23 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.24 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 20.25 Partnerships and Collaborations: Distribution by Focus Area
Table 20.26 Partnerships and Collaborations: Distribution by Number of Partnerships
Table 20.27 Most Active Players: Distribution by Location of Headquarters (Region-wise)
Table 20.28 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Table 20.29 Patent Analysis: Distribution by Type of Patent
Table 20.30 Patent Analysis: Distribution by Application Year
Table 20.31 Patent Analysis: Cumulative Distribution by Publication Year
Table 20.32 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Table 20.33 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Table 20.34 Patent Analysis: Distribution by CPC Symbols
Table 20.35 Patent Analysis: Emerging Focus Areas
Table 20.36 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
Table 20.37 Leading Industry Players: Distribution by Number of Patents
Table 20.38 Leading Non-Industry Players: Distribution by Number of Patents
Table 20.39 Leading Patent Assignees: Distribution by Number of Patents
Table 20.40 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Symbols)
Table 20.41 Patent Analysis: Distribution of Patents by Age (2019-2021)
Table 20.42 Protein Design and Engineering: Patent Valuation
Table 20.43 Clinical Trial Analysis: Scope and Methodology
Table 20.44 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2021
Table 20.45 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2021
Table 20.46 Clinical Trial Analysis: Distribution by Trial Phase and Number of Registered Trials
Table 20.47 Clinical Trial Analysis: Distribution by Trial Phase and Enrolled Patient Population
Table 20.48 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 20.49 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status, Pre-2010-2021
Table 20.50 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 20.51 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 20.52 Leading Industry Players: Distribution by Number of Registered Trials
Table 20.53 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 20.54 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 20.55 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 20.56 Global Protein Design and Engineering Services Market, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.57 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Protein Engineering Approach Used (USD Billion)
Table 20.58 Protein Design and Engineering Services Market, 202 and 2035: Distribution by Type of Protein (USD Billion)
Table 20.59 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of Application (USD Billion)
Table 20.60 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Type of End User (USD Billion)
Table 20.61 Protein Design and Engineering Services Market, 2021 and 2035: Distribution by Region (USD Billion)
Table 20.62 Protein Design and Engineering Services Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.63 Protein Design and Engineering Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.64 Protein Design and Engineering Services Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.65 Protein Design and Engineering Services Market in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.66 Protein Design and Engineering Services Market in MENA, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 20.67 Protein Design and Engineering Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report.

1. 13therapeutics
2. 9 Meters Biopharma
3. Ablynx
4. Absolute Antibody
5. Abzena
6. Accelero Biostructures 
7. Advanced Accelerator Applications
8. AffyPro
9. Aileron Therapeutics
10. Akashi Therapeutics
11. Allozymes
12. Allysta Pharmaceuticals
13. Altimmune
14. Ambrx
15. Amgen
16. Aminoverse
17. Amolyt Pharma
18. Ampio Pharmaceuticals
19. Amyndas Pharmaceuticals
20. Anji Pharmaceuticals
21. Apellis Pharmaceuticals
22. Apeptico
23. APIM Therapeutics
24. Apitope
25. Aquestive Therapeutics
26. Arch Biopartners
27. Arzeda
28. AsclepiX Therapeutics
29. Astellas Pharma
30. AstraZeneca
31. Atox Bio
32. Atreca
33. ATUM
34. August Bioservices
35. Aurinia Pharmaceuticals
36. Averin Biotech
37. Avilex Pharma
38. Bayer
39. Bicycle Therapeutics
40. BioLineRx
41. Biolingus
42. Biologics International
43. Biomarck Pharmaceuticals
44. BioMarin Pharmaceutical
45. BioMetis Technology
46. BioTickle
47. Boehringer Ingelheim
48. Boston Therapeutics
49. Bristol Myers Squibb
50. Broad Institute of MIT and Harvard
51. California Institute of Technology
52. CanBas
53. Cancer Research UK
54. candidum
55. Cara Therapeutics
56. Carmot Therapeutics
57. Cellivery Therapeutics
58. Cend Therapeutics
59. ChemPartner
60. Chiasma Pharma
61. China Agricultural University
62. Chondropeptix
63. ChromoTek
64. Chrysalis BioTherapeutics
65. Clinuvel Pharmaceuticals
66. Codex DNA
67. Codexis
68. CohBar
69. Columbia University
70. Constant Therapeutics
71. Creative Biolabs
72. Creative BioMart
73. Creative Biostructure
74. Creative Enzymes
75. CureDM
76. Curonz
77. Cyrus Biotechnology
78. Cytovation
79. Cytovia Therapeutics
80. Dana-Farber Cancer Institute
81. Dezyme
82. Diabetology
83. Diapin Therapeutics
84. DNASTAR
85. Early Drug Development Group (E2DG)
86. Eli Lilly
87. Emory University
88. Enantis 
89. Entera Bio
90. Enteris BioPharma
91. Enzymaster
92. EnzymeWorks
93. Esperance Pharmaceuticals
94. EUCODIS Bioscience 
95. EUPROTEIN 
96. Eurofins
97. EvoEnzyme
98. Evozyne
99. exonbio 
100. F4 Pharma
101. Factor Bioscience
102. Ferring Pharmaceuticals
103. FinsnoBio
104. Frontier Korea
105. Fujitsu 
106. FirstString Research
107. Follicum
108. Fornia BioSolutions
109. Frontier Biotechnologies
110. Fusion Antibodies
111. Genentech
112. Genervon Biopharmaceuticals
113. GeNext Genomics
114. Genomica
115. GenScript
116. Genus Oncology
117. Gila Therapeutics
118. Gilead Sciences
119. GlaxoSmithKline
120. GlioCure
121. Harvard University 
122. HELIOPOLIS BIOTECH
123. HighTide Therapeutics
124. iBio
125. ILC Therapeutics
126. Imcyse
127. ImmuPharma
128. Innovagen AB
129. Innovative Targeting Solutions
130. Inotrem
131. Inscripta
132. Integral Molecular
133. InterK Peptide Therapeutics
134. Issar Pharmaceuticals
135. iXpressGenes
136. Janssen Biotech
137. Kalos Therapeutics
138. Kerafast
139. La Jolla Pharmaceutical
140. LabGenius 
141. Laboratory of Computational Biology 
142. LakePharma (acquired by Curia)
143. Lassogen
144. Lead Discovery Siena
145. Leland Stanford Junior University
146. Longevity Biotech
147. LifeSpan BioSciences (LSBio)
148. Macromoltek
149. Massachusetts General Hospital
150. Massachusetts Institute of Technology
151. Mayo Clinic
152. MD Anderson Cancer Center
153. MedImmune
154. MElkin Pharmaceuticals
155. Memorial Sloan Kettering Cancer Center
156. Merck
157. MeSCue-Janusys
158. Mid-Atlantic BioTherapeutics (MABT)
159. Millennium Pharmaceuticals
160. Molecular Loop
161. Molecular Partners
162. Mologic
163. Molsoft
164. Nanomerics
165. National Cancer Institute (NCI)
166. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
167. Nestlé Health Science
168. Neurozon
169. Next Interactions
170. NextPharma
171. NoNO
172. Nostrum Biodiscovery
173. NovaCell Technology
174. Novartis
175. Novo Nordisk
176. NVIDIA
177. NYU Langone Health
178. Oak BioSciences
179. Olympic Protein Technologies (OPT) 
180. ONL Therapeutics
181. OpenEye Scientific
182. OPKO Health
183. Oramed Pharmaceuticals
184. OriMAbs
185. Ovoca Bio
186. Oxalo Therapeutics
187. Oxurion
188. Palatin Technologies
189. PEACCEL 
190. PEP-Therapy
191. PeptiDream
192. Peptilogics
193. Peptone 
194. Peptron
195. PharmaMar
196. Pieris Pharmaceuticals
197. PIN Pharma
198. Plabeltech
199. Polyclone Bioservices
200. Polyphor
201. Porton Pharma Solutions
202. Priavoid
203. ProLynx
204. ProMab Biotechnologies
205. ProMore Pharma
206. ProNeurogen
207. Protagonist Therapeutics
208. Protein Alternatives SL (PROALT)
209. Protein Design
210. ProteinQure
211. Proteus by Seqens
212. Pulmotect
213. Quantum Hi-Tech (China) Biological
214. Quantumzyme
215. Queen’s University Belfast
216. Radius Health
217. Rani Therapeutics
218. Ranomics
219. RD-BIOTECH
220. Regeneron Pharmaceuticals
221. RegeneRx Biopharmaceuticals
222. ReGenTree
223. Revolve Biotechnologies
224. Rhythm Pharmaceuticals
225. Roche
226. Safic-Alcan
227. Salix Pharmaceuticals
228. Sanofi
229. Santhera Pharmaceuticals
230. Sapience Therapeutics
231. Scotia Biologics
232. Scotia Biologics
233. Seachaid Pharmaceuticals
234. Selecta Biosciences
235. Sentebiolab
236. Serpin Pharma
237. SeSaM-Biotech
238. Soligenix
239. Soricimed Biopharma
240. Stealth BioTherapeutics
241. Structure Based Design (SBD)
242. Sutro Biopharma
243. Swedish Orphan Biovitrum (SOBI)
244. Synbio Technologies
245. Synbuild
246. SYNG Pharmaceuticals
247. Synthorx (acquired by Sanofi)
248. Takeda Pharmaceuticals
249. Tarsa Therapeutics
250. TC BioPharm
251. TCR2 Therapeutics
252. TearSolutions
253. Technical University of Denmark
254. TeselaGen Biotechnology
255. The University of Texas
256. TheraSource
257. Thermo Fisher Scientific
258. Topas Therapeutics
259. Twist Bioscience
260. TwoToBiotech
261. University of California, San Francisco (UCSF)
262. UCB Pharma
263. UCLA Technology Development Group
264. University of California
265. University of Chicago
266. University of Toronto
267. University of Washington
268. Vault Pharma
269. Vaxeal
270. Verne Global
271. Viatem
272. Vir Biotechnology
273. Watchmaker Genomics
274. Xen Biofluidx
275. Xencor
276. Xigen
277. XPose Therapeutics
278. YUMAB
279. Zealand Pharma
280. Zucara Therapeutics
281. Zummit Infolabs
282. Zymeworks
283. Zymvol Biomodeling